Variations in the metabolome in response to disease activity of rheumatoid arthritis

• Published in: BMC musculoskeletal disorders Vol. 17; no. 1; p. 353
• Main Authors: Tatar, Zuzana, Migne, Carole, Petera, Melanie, Gaudin, Philippe, Lequerre, Thierry, Marotte, Hubert, Tebib, Jacques, Pujos Guillot, Estelle, Soubrier, Martin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.08.2016; BioMed Central
• Subjects: Adalimumab - therapeutic use; Adult; Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - metabolism; Care and treatment; Chromatography, Reverse-Phase; Complications and side effects; Discriminant Analysis; Etanercept - therapeutic use; Female; Food and Nutrition; Human health and pathology; Humans; Infliximab - therapeutic use; Influence; Life Sciences; Male; Mass Spectrometry - methods; Metabolome; Middle Aged; Prognosis; Rheumatoid arthritis; Treatment Outcome; Tumor necrosis factor; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Drug response biomarkers; Metabolomics; Anti-TNF-alpha therapy; Rheumatoid arthritis; anti-TNF-alpha therapy; drug response biomarkers; metabolomics; profil métabolique; échantillon de plasma; rheumatoid arthritis; facteur de nécrose tumorale

Anti-Tumor Necrosis Factor (TNF) therapies are able to control rheumatoid arthritis (RA) disease activity and limit structural damage. Yet no predictive factor of response to anti-TNF has been identified. Metabolomic profile is known to vary in response to different inflammatory rheumatisms so deter...